

Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-875A31FF-A187-4A3C-B3AD-824566CC5A9A_3_en-US
DOI: https://doi.org/10.31003/USPNF_M27700_03_01
DOI Ref: h1cet

© 2025 USPC
Do not distribute

Disulfiram Tablets

DEFINITION

Disulfiram Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of disulfiram ($C_{10}H_{20}N_2S_4$).

IDENTIFICATION

Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#): 197A or 197K▲ (CN 1-May-2020)

Standard: [USP Disulfiram RS](#)

Sample: A portion of powdered Tablets

Acceptance criteria: Meet the requirements

- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY

• PROCEDURE

Buffer: 6.8 g/L of [monobasic potassium phosphate](#) in [water](#). Adjust with [45% potassium hydroxide TS](#) to a pH of 7.0.

Mobile phase: [Methanol](#) and *Buffer* (70:30)

Standard stock solution: 1 mg/mL of [USP Disulfiram RS](#) in [alcohol](#). Use this solution within 5 days.

Standard solution: 0.02 mg/mL of [USP Disulfiram RS](#) from the *Standard stock solution* diluted with *Mobile phase*. Use this solution within 1 day.

Sample stock solution: Nominally 1 mg/mL of disulfiram from Tablets prepared as follows. Powder NLT 20 Tablets and transfer a suitable portion of the powder to an appropriate volumetric flask. Add 70% of the flask volume of [alcohol](#) and swirl, sonicate for about 5 min, and shake by mechanical means for 30 min or until dissolved. Dilute with [alcohol](#) to volume and pass through a suitable filter. Use the filtrate. Use this solution within 5 days.

Sample solution: Nominally 0.02 mg/mL of disulfiram from *Sample stock solution* in *Mobile phase*. Use this solution within 1 day.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 250 nm

Column: 3.9-mm × 15-cm; 5-μm packing [L1](#)

Flow rate: 1 mL/min

Injection volume: 20 μL

Run time: NLT 1.5 times the retention time of disulfiram

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 1.5

Relative standard deviation: NMT 1.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of disulfiram ($C_{10}H_{20}N_2S_4$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Disulfiram RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of disulfiram in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS• **DISINTEGRATION (701)**

Time: 15 min, the use of disks being omitted

• **UNIFORMITY OF DOSAGE UNITS (905):** Meet the requirements**IMPURITIES**• **ORGANIC IMPURITIES**

Buffer: 6.8 g/L of [monobasic potassium phosphate](#) in [water](#). Adjust with [45% potassium hydroxide TS](#) to a pH of 7.0.

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Buffer (%)	Methanol (%)
0	60	40
8	30	70
12.0	30	70
12.1	60	40
16.0	60	40

Diluent: [Methanol](#) and *Buffer* (50:50)

System suitability solution: 0.05 mg/mL of [USP Disulfiram RS](#) and 0.01 mg/mL of [sulfiram](#) in *Diluent*. Use this solution within 1 day.

Standard stock solution: 0.25 mg/mL of [USP Disulfiram RS](#) in methanol. Use this solution within 1 day.

Standard solution: 0.002 mg/mL of [USP Disulfiram RS](#) from *Standard stock solution* in *Diluent*. Use this solution within 1 day.

Sensitivity solution: 0.001 mg/mL of [USP Disulfiram RS](#) from *Standard solution* in *Diluent*. Use this solution within 1 day.

Sample stock solution: Nominally 2.5 mg/mL of disulfiram from NLT 5 Tablets in [methanol](#). Store at 4° and use it within 2 h.

Sample solution: Nominally 1 mg/mL of disulfiram from *Sample stock solution* in *Diluent*. Store at 4° and use it within 2 h.

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: UV 250 nm

Column: 3.9-mm × 15-cm; 5-μm, 300 Å packing [L1](#)

Autosampler temperature: 4°

Flow rate: 1 mL/min

Injection volume: 15 μL

System suitability

Samples: *System suitability solution*, *Standard solution*, and *Sensitivity solution*

[NOTE—See [Table 2](#) for relative retention times.]

Suitability requirements

Resolution: NLT 8.0 between [sulfiram](#) and disulfiram, *System suitability solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of disulfiram from the *Standard solution*

C_S = concentration of [USP Disulfiram RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of disulfiram in the *Sample solution* (mg/mL)

F = relative response factor (see [Table 2](#))

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.1%.

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Diethyldithiocarbamic acid	0.18	1.2	0.2
Tetraethylthiourea ^a	0.69	1.1	0.2
Sulfiram ^b	0.80	0.55	0.2
Disulfiram	1.0	—	—
Any other individual impurity	—	1.0	0.2
Total impurities	—	—	1.0

^a 1,1,3,3-Tetraethylthiourea.^b Diethylthiocarbamic thioanhydride.**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers. Store at controlled room temperature.
- **USP REFERENCE STANDARDS (11).**
[USP Disulfiram RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DISULFIRAM TABLETS	Documentary Standards Support	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 43(6)

Current DocID: GUID-875A31FF-A187-4A3C-B3AD-824566CC5A9A_3_en-US**DOI:** https://doi.org/10.31003/USPNF_M27700_03_01**DOI ref:** [h1cet](#)